• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确认后部皮质萎缩中的淀粉样蛋白形成过程:Aβ42/Aβ40 比值的价值。

Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.

机构信息

CHRU de Tours, Tours, France.

出版信息

J Alzheimers Dis. 2013;33(3):775-80. doi: 10.3233/JAD-2012-121267.

DOI:10.3233/JAD-2012-121267
PMID:22986776
Abstract

Posterior cortical atrophy (PCA) is characterized by progressive higher-order visuo-perceptual dysfunction and praxis declines. This syndrome is related to several underlying diseases, including Alzheimer's disease (AD), sometimes involving an amyloidogenic process. The aims of the study were to 1) define cerebrospinal fluid (CSF) biomarker profiles in PCA patients compared to AD patients and 2) explore the amyloidogenic process through the Aβ(42)/Aβ(40) ratio in PCA patients to elucidate the underlying disease in vivo. CSF biomarker analysis (t-tau, p-tau, Aβ(42), and Aβ(42)/Aβ(40) ratio) and neuropsychological examination were performed in 22 PCA patients and compared with those of age-matched AD patients. Associated clinical neurological signs were investigated (e.g., extrapyramidal motor signs, myoclonus). CSF biomarker profiles did not differ significantly between the PCA and AD groups; 82% of patients with PCA fulfilled the biological criteria for typical AD with abnormal levels of the three markers and 18% of PCA patients presented atypical CSF profiles. All PCA patients with associated clinical neurological signs presented typical AD CSF profiles. The clinical presentations of these patients were similar to other PCA subjects. The Aβ(42)/Aβ(40) ratio for all PCA patients, including those with atypical CSF profiles, was decreased. Most PCA syndromes were associated with CSF biomarkers suggestive of AD, even in cases with associated clinical neurological signs. The amyloidogenic process was confirmed by the decreased Aβ(42)/Aβ(40) ratio for all patients. This analysis avoids misdiagnosis in the presence of physiologically high or low amyloid peptide production rates and provides information in vivo to improve understanding of the underlying disease in PCA.

摘要

后部皮质萎缩症(PCA)的特征是进行性高级视知觉功能障碍和动作执行能力下降。这种综合征与几种潜在疾病有关,包括阿尔茨海默病(AD),有时涉及淀粉样蛋白形成过程。本研究的目的是 1)定义 PCA 患者与 AD 患者相比的脑脊液(CSF)生物标志物谱,2)通过 PCA 患者的 Aβ(42)/Aβ(40)比值探索淀粉样蛋白形成过程,以阐明体内潜在疾病。对 22 例 PCA 患者进行了 CSF 生物标志物分析(t-tau、p-tau、Aβ(42)和 Aβ(42)/Aβ(40)比值)和神经心理学检查,并与年龄匹配的 AD 患者进行了比较。研究了相关的临床神经体征(如锥体外系运动体征、肌阵挛)。PCA 和 AD 组之间的 CSF 生物标志物谱无显著差异;82%的 PCA 患者符合典型 AD 的生物学标准,即三种标志物水平异常,18%的 PCA 患者表现出非典型 CSF 谱。所有伴有相关临床神经体征的 PCA 患者均表现出典型 AD 的 CSF 谱。这些患者的临床表现与其他 PCA 患者相似。所有 PCA 患者(包括 CSF 谱不典型的患者)的 Aβ(42)/Aβ(40)比值均降低。大多数 PCA 综合征与提示 AD 的 CSF 生物标志物有关,即使在伴有相关临床神经体征的情况下也是如此。淀粉样蛋白形成过程通过所有患者(包括 Aβ(42)/Aβ(40)比值降低)得到证实。该分析避免了在生理上高或低淀粉样肽产生率存在的情况下的误诊,并提供了体内信息,以改善对 PCA 中潜在疾病的理解。

相似文献

1
Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.确认后部皮质萎缩中的淀粉样蛋白形成过程:Aβ42/Aβ40 比值的价值。
J Alzheimers Dis. 2013;33(3):775-80. doi: 10.3233/JAD-2012-121267.
2
CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.脑脊髓液中的 tau 和 Aβ(1-42)在后部皮质萎缩中的变化。
Dement Geriatr Cogn Disord. 2010;29(6):530-3. doi: 10.1159/000314679. Epub 2010 Jul 1.
3
Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.脑脊髓液中的淀粉样β寡聚体与阿尔茨海默病患者的认知能力下降有关。
J Alzheimers Dis. 2012;29(1):171-6. doi: 10.3233/JAD-2012-111361.
4
BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.脑脊髓液中的 BACE1 活性及其与 AD 病理标志物的关系。
J Alzheimers Dis. 2010;20(1):253-60. doi: 10.3233/JAD-2010-1367.
5
Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.脑脊液生物标志物在阿尔茨海默病与其他皮质性痴呆的鉴别诊断中的应用。
J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):240-6. doi: 10.1136/jnnp.2010.207183. Epub 2010 Aug 27.
6
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.阿尔茨海默病的脑脊液生物标志物与皮质脑活检结果相关。
Neurology. 2012 May 15;78(20):1568-75. doi: 10.1212/WNL.0b013e3182563bd0. Epub 2012 Apr 18.
7
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.在常规实践中,将β淀粉样蛋白42(Aβ₄₂)/β淀粉样蛋白40(Aβ₄₀)比值与脑脊液生物标志物磷酸化tau蛋白(P-tau)和Aβ₄₂一起使用,可提高阿尔茨海默病病理生理过程的证据水平。
J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.
8
Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.在阿尔茨海默病患者、轻度认知障碍患者和健康对照者的脑脊液中,胱抑素 C 水平与 Abeta42 和 tau 水平呈正相关。
J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.
9
Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.脑脊液生物标志物与记忆在从健康受试者到 AD 患者的连续体上呈现出不同的关联。
J Alzheimers Dis. 2011;23(2):319-26. doi: 10.3233/JAD-2010-101422.
10
Biomarker profiles and their relation to clinical variables in mild cognitive impairment.轻度认知障碍中的生物标志物特征及其与临床变量的关系。
Neurocase. 2005 Feb;11(1):8-13. doi: 10.1080/13554790490896785.

引用本文的文献

1
Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants.阿尔茨海默病的生物标志物:在早期和鉴别诊断以及识别非典型变异中的作用。
Alzheimers Res Ther. 2023 Oct 13;15(1):175. doi: 10.1186/s13195-023-01314-6.
2
Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score.重新概念化用于评估痴呆风险的埃尔朗根评分:埃尔朗根评分。
J Alzheimers Dis. 2023;96(1):265-275. doi: 10.3233/JAD-230524.
3
Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
ADNIGO/2 参与者 CSF 中淀粉样蛋白-β肽的 LC-MS/MS 参考方法分析和临床性能。
Clin Chem. 2020 Apr 1;66(4):587-597. doi: 10.1093/clinchem/hvaa012.
4
Frontotemporal dementia is the leading cause of "true" A-/T+ profiles defined with Aβ ratio.额颞叶痴呆是以淀粉样蛋白(Aβ)比值定义的“真正”A-/T+脑影像特征的主要病因。
Alzheimers Dement (Amst). 2019 Feb 15;11:161-169. doi: 10.1016/j.dadm.2019.01.001. eCollection 2019 Dec.
5
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.通过免疫或基于质谱的检测方法提高 CSF 中淀粉样β肽回收率的前分析方法。
Alzheimers Res Ther. 2018 Nov 28;10(1):118. doi: 10.1186/s13195-018-0445-0.
6
Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers.基于阿尔茨海默病脑脊液生物标志物的后部皮质萎缩谱中的萎缩、代谢和认知。
Neuroimage Clin. 2018;20:1018-1025. doi: 10.1016/j.nicl.2018.10.010. Epub 2018 Oct 10.
7
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.神经退行性痴呆的脑脊液和血液生物标志物:世界生物精神病学学会联合会精神病学生物标志物工作组的共识更新。
World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27.
8
Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?脑穿透性 BACE1 抑制剂能否作为抗脑动脉淀粉样血管病药物?
BMC Neurol. 2017 Aug 25;17(1):163. doi: 10.1186/s12883-017-0942-y.
9
Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.内侧颞叶萎缩的视觉评分与早发性阿尔茨海默病临床变体中的脑脊液tau指数相关。
Dement Geriatr Cogn Disord. 2017;44(1-2):45-54. doi: 10.1159/000477718. Epub 2017 Jul 5.
10
Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.在阿尔茨海默病中,脑脊液Aβ42/40比Aβ42与淀粉样蛋白PET的对应性更好。
J Alzheimers Dis. 2017;55(2):813-822. doi: 10.3233/JAD-160722.